Cue Biopharma reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million year-over-year, driven by milestones from its Boehringer Ingelheim partnership. The company recorded a significant net loss of $153.1 million, primarily reflecting heavy one-time expenditures and non-cash charges associated with the licensing of CUE-221 and a strategic management transformation.
Key Highlights
- Research and development expenses surged to $49.0 million, including a $20.0 million upfront cash payment for the CUE-221 license and $20.0 million in warrant-related non-cash charges.
- General and administrative expenses reached $46.6 million, impacted by $23.0 million in management integration costs and $19.7 million in non-cash stock-based compensation.
- A net non-cash loss of $63.1 million was recognized in other expenses related to the fair value measurement of liability-classified warrants issued under the new license agreement.
- Liquidity was bolstered post-quarter by a $50 million private placement financing, intended to support upcoming Phase 2 data readouts for CUE-221.